Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Nanomedicine. 2017 Jan 20;13(4):1353–1362. doi: 10.1016/j.nano.2017.01.009

Figure 6.

Figure 6

Immunohistochemistry compares the pharmacodynamics effects of SN-38 in the tumor from irinotecan compared to delivery by IT-4 . (A) mmunohistochemical staining of γ-H2AX for the presence of DNA double stranded breaks at time points between 24-144 hours showing irinotecan treatment compared to IT-141 treatment in HT-29 colorectal tumor model. (B) Quantification of γ-H AX positive stained cells at same time points (n ≥ 2 tumors). Results represent means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. (C) Intravenous administration of IT-141 results in more than a 10-fold exposure of SN-38 over irinotecan to the tumor compartment. IT-141 had an SN-38 exposure of (AUC0-24hrs) 7.2 compared to 0.65 of SN-38 following irinotecan administration.